A consortium‑driven framework for expanding access to interventional neurosurgical cell therapy for Parkinson's disease

Parkinson's disease (PD) is a compelling target for dopaminergic cell-replacement therapy. Transitioning PD cell therapy from academic medical center trials to broad clinical availability requires coordinated solutions across manufacturing, surgical delivery, regulatory alignment, reimbursement, workforce development, and long-term infrastructure. This Expert Insight proposes a consortium-driven framework to expand access to interventional neurosurgical cell therapy for PD through a coherent, end-to-end delivery ecosystem linking standardized products, a tiered delivery network, scalable manufacturing, unified quality systems, parallel regulatory and payer engagement, and a mandatory longitudinal registry – offering a practical pathway to transition PD cell therapy from a small-batch, site-specific intervention to a reproducible, scalable, and equitable component of modern neurological care.

A consortium-driven framework proposes transitioning Parkinson's disease cell therapy from small-batch, centre-specific trials to a reproducible, equitable delivery ecosystem – linking standardized PSC-derived dopaminergic products, a tiered surgical network, scalable GMP manufacturing, unified quality systems, and a mandatory longitudinal registry to enable broad, safe clinical access.

What you will learn

01

How a precompetitive consortium can standardize shared domains – referral criteria, accreditation, registry architecture – while preserving sponsor-specific CMC and proprietary procedures

02

How a two-tier delivery network (Tier 1 regional hubs and Tier 2 accredited satellite centres) supported by tele-proctoring can expand procedural capacity equitably

03

How parallel regulatory engagement, outcomes-based reimbursement, workforce credentialing, and a mandatory registry form the cross-cutting foundations of a scalable PD cell therapy system

Consortium delivery pathway

1

Patient identification & harmonized eligibility criteria

2

Scalable GMP manufacturing & cold-chain supply

3

Tiered delivery network: Tier 1 hubs & Tier 2 satellite centres

4

Standardized stereotactic surgical delivery & iMRI verification

5

Perioperative care, long-term follow-up & registry surveillance

Key interests

Parkinson's Disease

Cell Therapy

PSC-Derived Dopaminergic Neurons

Neurosurgical Delivery

GMP Manufacturing

Consortium Framework

Regulatory Strategy

Health Equity